Rituximab biosimilar evaluated by network meta-analysis
نویسندگان
چکیده
منابع مشابه
analysis of power in the network society
اندیشمندان و صاحب نظران علوم اجتماعی بر این باورند که مرحله تازه ای در تاریخ جوامع بشری اغاز شده است. ویژگیهای این جامعه نو را می توان پدیده هایی از جمله اقتصاد اطلاعاتی جهانی ، هندسه متغیر شبکه ای، فرهنگ مجاز واقعی ، توسعه حیرت انگیز فناوری های دیجیتال، خدمات پیوسته و نیز فشردگی زمان و مکان برشمرد. از سوی دیگر قدرت به عنوان موضوع اصلی علم سیاست جایگاه مهمی در روابط انسانی دارد، قدرت و بازتولید...
15 صفحه اولAdalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
Sirs, In pre-approval trials of biosimilars, fewer patients are evaluated as compared with originators. For this reason, some physicians are reluctant to employ biosimilars in clinical practice and prefer originators (1). An original approach to strengthen the clinical evidence supporting biosimilars has recently been described (2-4). According to this method, a network meta-analysis is carried...
متن کاملAutomating network meta-analysis.
Mixed treatment comparison (MTC) (also called network meta-analysis) is an extension of traditional meta-analysis to allow the simultaneous pooling of data from clinical trials comparing more than two treatment options. Typically, MTCs are performed using general-purpose Markov chain Monte Carlo software such as WinBUGS, requiring a model and data to be specified using a specific syntax. It wou...
متن کاملRituximab for Rheumatoid Arthritis: A Meta-Analysis and systematic Review
Background: Rituximab (RTX) is a biological agent used for the treatment of refractory rheumatoid arthritis (RA). The present systematic review and meta-analysis update the safety and efficacy of RTX for the treatment of RA in data published since 2006. Methods: We searched PubMed from January 2000 to March 2010, and recent ACR Annual meeting abstracts for randomized (RCT) and non-randomized, c...
متن کاملComparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
AIMS To evaluate potential differences between PF-05280586 and rituximab sourced from the European Union (rituximab-EU) and USA (rituximab-US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity assessment of PF-05280586. METHODS A randomised, double-blind, pharmacokinetic similarity trial...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2017
ISSN: 0390-6078,1592-8721
DOI: 10.3324/haematol.2017.175042